← FDA DRUG APPROVALS

FDA ANDA · ANDA201539

OXACILLIN

oxacillin sodium

Sponsor: EUGIA PHARMA SPECLTS

APPLICATION
ANDA201539
TYPE
ANDA
ORIGINAL APPROVAL
2013-01-18
LATEST ACTION
2018-08-01
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OXACILLIN SODIUMPrescription
OXACILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
OXACILLIN SODIUMPrescription
OXACILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2018-08-01Manufacturing (CMC) · Supplement 7AP
2013-04-26Labeling · Supplement 1 · standardAP
2013-01-18Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →